However, in the same breath the JCD notes that Wellbutrin is classed as Category 'B', described by them as having no evidence of risk in humans.
What everyone can agree on, it appears, is that psychotropic drugs such as antidepressants cross the placenta. It is for this reason that the US Food and Drug Administration (FDA) does not approve antidepressants for use by pregnant women, due to the concern for potential Wellbutrin birth defects.
That said, given the rise in the percentage of women who continue on with antidepressants during pregnancy, together with the medical authority on the part of doctors to prescribe such medications off-label to benefit their patients, the FDA has at least acknowledged the situation by issuing a black box warning with regard to the potential for suicidal behavior and suicidality in children and adolescents with MDD and other psychiatric disorders.
Wellbutrin does not carry FDA approval for treatment of depression in children, as it could make that depression worse.
Judging by various postings to blog sites by Wellbutrin patients, such concerns over anxiety and deepening depression are well founded even in adults.
READ MORE WELLBUTRIN LEGAL NEWS
Wellbutrin patient Adrian noted that he suffered from a panic disorder, and described his situation as 'tearing up' at just about anything and everything since starting on Wellbutrin XL.
As for Wellbutrin and pregnancy, SafeFetus.com duly highlights Wellbutrin in Category C as an FDA Pregnancy Risk factor, with an increase in congenital defects reported without fetotoxicity in animals. With limited human data reported, use of Wellbutrin during the first trimester was found to be without teratogenic effects. SafeFetus.com, a resource for pregnant women and mothers-to-be, notes the observation that Wellbutrin is excreted into breast milk, and that the effects on nursing infants—including Wellbutrin adverse effects—are unknown.